.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,544,967

« Back to Dashboard

Details for Patent: 6,544,967

Title: Method for inhibiting bone resorption
Abstract:Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
Inventor(s): Daifotis; Anastasia G. (Westfield, NJ), Santora, II; Arthur C. (Watchung, NJ), Yates; A. John (Westfield, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Filing Date:Jan 08, 2001
Application Number:09/756,562
Claims:1. A pharmaceutical composition comprising about 140 mg, on an alendronic acid active basis, of a bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof.

2. A pharmaceutical composition according to claim 1 wherein said pharmaceutically acceptable salt is selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts.

3. A pharmaceutical composition according to claim 2 wherein said pharmaceutically acceptable salt is a sodium salt.

4. A pharmaceutical composition according to claim 3 wherein said pharmaceutically acceptable salt is alendronate monosodium trihydrate.

5. A pharmaceutical composition according to claim 1 in the form of a tablet.

6. A pharmaceutical composition according to claim 2 in the form of a tablet.

7. A pharmaceutical composition according to claim 3 in the form of a tablet.

8. A pharmaceutical composition according to claim 4 in the form of a tablet.

9. A pharmaceutical composition according to claim 1 in the form of a capsule.

10. A pharmaceutical composition according to claim 2 in the form of a capsule.

11. A pharmaceutical composition according to claim 3 in the form of a capsule.

12. A pharmaceutical composition according to claim 4 in the form of a capsule.

13. A pharmaceutical composition according to claim 1 in the form of a liquid.

14. A pharmaceutical composition according to claim 2 in the form of a liquid.

15. A pharmaceutical composition according to claim 3 in the form of a liquid.

16. A pharmaceutical composition according to claim 4 in the form of a liquid.

17. A pharmaceutical composition according to any of claims 1-16 wherein said pharmaceutical composition is an oral composition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc